MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Medical Devices & Technology (Technology)
*Driving Forces: Telemedicine,Telehealth, Mobile Health, mHealth, Virtual, Digital Health, DTx (Digital Therapeutics)
*Driving Forces: Telemedicine,Telehealth, mHealth & Home Health (Sectors)
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
*Pioneers: Cardiology & Cardiovascular
Medical & Clinical Specialities
Diseases, Illnesses, Injury & Injuries
Cancer, Oncology
Immuno - Oncology
Parents
Cancer, Oncology
Children
"Parker Institute for Cancer Immunotherapy"
*Adaptive TCR Corporation's platform technology focuses on the field of genomics immunology.
*Funding: Immunology, Immunity, ImmunoTherapy
*Immuno-oncology
*Immunoscience
*Monoclonal antibodies focus the body’s immunological response specifically against a target cancer cell, and have been used in several approved oncology drugs, including Bristol-Myers Squibb's Herceptin for breast cancer.
2011: Intrexon Corporation Acquires Immunologix Inc (2011)
2012: Heat Biologics raising $4M, eyes more cancer immunotherapy clinical trials (2012)
2013: Immune Design Grabs $32.5M, Cashing in on Cancer Immunotherapy Rush (2013)
2014: Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial
2014: Immuno-Oncology Startup CoStim Pharmaceuticals Acquired By Novartis
2014: Merck Co Inc Turns To Rivals Such As Amgen, Incyte And Pfizer Inc. (PFE) To Accelerate Cancer-Immunotherapy Program
2016: AbbVie Bolsters Immunology Business, Acquires Boehringer Drug
2022: NCI_RFI_Seeking Input for the National Cancer Institute (NCI) on Advancing Research in Immuno-oncology, Immunoprevention, and/or Immunotherapy.
2024: Immune Cell Breakthrough: Scientists Discover a Hidden Ally in the Fight Against Cancer
BeOne Medicines, formerly, BeiGene, Ltd (NASDAQ: BGNE)
Biotech company combating fatal diseases through the activation and mobilization of the body's immune system using immunotherapy.
CAR-T cell immunotherapy
Exelixis, Inc. (NASDAQ: EXEL)*
Immunocore Holdings plc (NASDAQ: IMCR)*
ImmunoGen Inc. (NASDAQ: IMGN)
Immunogenetics Rangos Research Center
ImmunoGenetix Therapeutics
Immunologix
Immunome, Inc. (NASDAQ: IMNM)*
Immunomedics (NASDAQ:IMMU)
Immunomic Therapeutics, Inc
Immunovaccine
Immunovent
Juno Therapeutics (JUNO)
Kite Pharma (NASDAQ:KITE)*
Merck & Co., Inc. (NYSE:MRK)
Oxford Immunotec Global
Velox™ is a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases using either nucleic acid or immuno-assays.
Working on an immunomodulatory response to cancer.